Feasibility and safety analysis of laryngeal mask implantation induced by remazolam combined with remifentanil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052136

Enrollment

Unknown

Registered

2021-10-20

Start date

2022-01-30

Completion date

Unknown

Last updated

2022-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induction of General anesthesia

Interventions

Experimental group:0.3mg/kgRemimazolam+1.2µg/kgremifentanial

Control group:2.0mg/kgPropofol+1.2µg/kgremifentanial

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.ASA I-II; 2.BMI:18 to 24, aged 18 to 60 years.

Exclusion criteria

Exclusion criteria: 1. Exclude the risk of aspiration such as full stomach; 2. Allergic to any drug; 3. History of upper respiratory tract infection and asthma; 4. History of drug or alcohol abuse; expected airway difficulty; 5. Cardiovascular and cerebrovascular diseases, hypertension, heart disease, cerebral infarction; 6. Epilepsy and other patients.

Design outcomes

Primary

Measure	Time frame
Muzi Score System while inserting laryngeal mask ;	—

Secondary

Measure	Time frame
heart rate blood pressure;Adverse effects before successful laryngeal mask placement;Use of vascular drugs before induction to 4 min after laryngeal mask placement;during of eyelash reflection disappear;operation time of laryngeal mask insertion;times of attempts to insert a laryngeal mask;Time from the start of induction to the successful placement of the laryngeal mask;peak pressure;	—

Countries

China

Contacts

Public ContactMeng Qingtao

Rinmin Hospital of Wuhan University

mengqingtao2018@126.com+86 13995569560

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026